Aktuellt
SENASTE
We leave our estimates broadly unchanged after Q1. Bactiguard’s Q1 was a slow quarter with an organic sales decline after four consecutive quarters of growth although costs declined q/q on a positive note. Bactiguard stated that its development of a US go-to strategy is a key focus for 2023, something we think partly is behind the cost increases recently. Overall, we still argue most prerequisites for strong growth are in place.
LÄS MER
